



Medication-assisted treatment paves road to recovery

In 2014, approximately 21.5 million Americans aged 12 or older (8.1 percent) had a substance use disorder (SUD) in the past year, according to the Substance Abuse and Mental Health Services Administration (SAMHSA).¹ For individuals suffering from substance use disorders—and those poised on the edge of addiction—making it through each day of recovery can be a daunting challenge.

Hope for the future

Numerous studies² have demonstrated a significant role for pharmacotherapy in augmenting the treatment of a variety of substance abuse disorders—and Magellan took note. Based on professional standards, such as those developed by the American Psychiatric Association's Physician Consortium for Performance Improvement®, a taskforce of Magellan clinical leaders created the medication-assisted treatment (MAT) program.

What is MAT?

Our national initiative seeks to increase the use of acamprosate, naltrexone (both in oral and injectable form), buprenorphine—and new medications

as their proven benefits emerge—in treatment of substance use disorders where clinically appropriate. The program not only focuses on patients who have been discharged from inpatient substance use treatment programs, but also targets individuals receiving outpatient case or disease management services. Through MAT measures, Magellan monitors the number of cases in which physicians are prescribing medications and follows member readmission rates.

As part of this intervention, Magellan continually collaborates with its health plan partners to help facilitate the incorporation of these medications into client formularies. Additionally, Magellan focuses on provider

“For some patients, traditional psychosocial treatments alone are not enough to maintain sobriety. We are confident that the use of these medications as a core component of treatment planning will help reduce relapse among our members with substance use disorders.”

– Gary M. Henschen, M.D.
Chief Medical Officer,
Magellan Healthcare

education efforts to illustrate the importance of using appropriate medications when developing members' substance use disorder treatment plans.

1. Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Retrieved from <http://www.samhsa.gov/data/>
2. Vo HT, Robbins E, Westwood M, Lezama D, Fishman M. Relapse prevention medications in community treatment for young adults with opioid addiction. *Subst Abus* 2016 • Timko C, Schultz NR, Cucciare MA, Vittorio BA, Garrison-Diehn CG. Retention in medication-assisted treatment for opiate dependence: a systematic review. *Journal of Addictive Diseases* 2016; 35(1): 22-35 • Mee-Lee D, Shulman GD, Fishman MJ, Gastfriend DR, Miller MM, eds. *The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions*. 3rd ed. Carson City, NV: The Change Companies®; 2013 • Dunn KE, Strain EC. Pretreatment alcohol drinking goals are associated with treatment outcomes. *Alcohol Clin Exp Res* 2013; 37(10): 1745-1752 • Mauger S, Fraser R, Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. *Neuropsychiatr Dis Treat* 2014; 10:587-598 • Neumann AM, Blondell RD, Azadfar M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. *Addict Behav* 2013; 38(11): 2724-8 • Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-Tackling the opioid overdose epidemic. *N Engl J Med* 2014; 370(22): 2064-65.